

DT06 Rec'd PCT/PTO

9 AUG 2002

PCT
#

Page 1 of 3

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

In re application : Per-Ake Nygren, Mathias Uhlen and Olof Nord
Serial No. : 10/030,652
Filed : November 9, 2001
For : SELF-ASSEMBLING BIOMOLECULAR
STRUCTURES
Examiner :
Attorney Docket : 102359-100
Group Art Unit :
Confirmation No. : 4666

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on 23 AUG 2002.

By

Todd E. Garabedian
Todd E. Garabedian, Ph.D.
Registration No. 39,197
Attorney for Applicant(s)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
United States Patent and Trademark Office
Washington, DC 20231

Dear Sir:

Pursuant to 37 C.F.R. §1.56, the Examiner is respectfully requested to consider the references cited on attached Form PTO-1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- ☒ 1. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.
- ☐ 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
- ☐ a. Each item of information contained on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1); and no fee is required under 37 C.F.R. §1.17(p).
- ☐ b. No item of information cited on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2); and no fee is required under 37 C.F.R. §1.17(p).
- ☐ Please charge Deposit Account No. 23-1665 in the amount of \$240.00 in payment of the fee under 37 C.F.R. §1.17(p). Two additional copies of this Information Disclosure Statement are enclosed.
- ☐ A check in the amount of \$240.00 is attached hereto in payment of the fee under 37 C.F.R. §1.17(p).
- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. It is hereby requested that the Information Disclosure Statement be considered.
- ☐ a. Each item of information contained on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).
- ☐ b. No item of information cited on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than

three months prior to the filing of this Information Disclosure Statement.
37 C.F.R. §1.97(e)(2).

- [] Please charge Deposit Account No. 23-1665 in the amount of \$130.00 in payment of the fee under 37 C.F.R. §1.17(i)(1). Two additional copies of this Information Disclosure Statement are enclosed.
- [] A check in the amount of \$130.00 is attached hereto in payment of the fee under 37 C.F.R. §1.17(i)(1).

The undersigned represents that the closest art of which he is presently aware has been cited herein and understands that this statement shall not be construed as a representation that no better art exists or that a thorough patentability search has been made.

The undersigned further represents that the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

Respectfully submitted,

PER-AKE NYGREN, MATHIAS UHLEN
AND OLOF NORD


By Todd E. Garabedian
Todd E. Garabedian, Ph.D.
Registration No. 39,197
Attorney for Applicants

WIGGIN & DANA LLP
One Century Tower
New Haven, CT 06508-1832

Telephone : (203) 498-4400
Telecopier: (203) 782-2889

Date: 23 AUG 2002

FORM PTO-1449


**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
PATENT DOCKET NO. 102359-100

SERIAL NO. 10/030,652

APPLICANTS: PER-AKE NYGREN, MATHIAS UHLEN AND OLOF NORD

FILING DATE: November 9, 2001

GROUP:
U.S. PATENT DOCUMENTS

EXAMINER INITIAL*	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPR.

FOREIGN PATENT DOCUMENTS

DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION Yes No

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

~	NORD, K ET AL: NATURE BIOTECHNOLOGY, vol. 15, no. 8, August 1997 (1997-08), pages 772-777.
~	PETKA, W A ET AL: SCIENCE, vol. 281, 17 June 1998 (1998-06-17), pages 389-392.
~	VOSS, S and SKERRA, A: PROTEIN ENGINEERING, vol. 10, no. 8, 1997, pages 975-982.
~	NORD, K ET AL: JOURNAL OF BIOTECHNOLOGY, vol. 80, 2000, pages 45-54.
~	GUNNERIUSSEN, E ET AL: PROTEIN ENGINEERING, vol. 12, no. 10, October 1999 (1999-10), pages 873-878.
~	GROB, P ET AL: IMMUNOTECHNOLOGY, vol. 4, no. 2, October 1998 (1998-10), pages 155-163.

EXAMINER: MARK NAVARRO

DATE CONSIDERED: 1/26/05

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



DT20 Rec'd PCT/PTO : 9 MAY 2003 ^{PCT}

Page 1 of 3

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

In re application : Per-Åke Nygren, Mathias Uhlén and Olof Nord
Serial No. : 10/030,652
Filed : November 9, 2001
For : SELF-ASSEMBLING BIOMOLECULAR
STRUCTURES
Examiner :
Attorney Docket : 102359-100
Group Art Unit :
Confirmation No. : 4666

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on 16 MAY 2003

By Todd E. Garabedian
Todd E. Garabedian, Ph.D.
Registration No. 39,197
Attorney for Applicant(s)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.56, the Examiner is respectfully requested to consider the references cited on attached Form PTO-1449. A copy of each reference (if not previously submitted) is enclosed. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- [X] 1. This Information Disclosure Statement is being filed within three months of the U. S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

- ☐ 2. This Information Disclosure Statement is being filed more than three months after the U. S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
- ☐ a. Each item of information contained on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1); and no fee is required under 37 C.F.R. §1.17(p).
- ☐ b. No item of information cited on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2); and no fee is required under 37 C.F.R. §1.17(p).
- ☐ Please charge Deposit Account No. 23-1665 in the amount of \$240.00 in payment of the fee under 37 C.F.R. §1.17(p). Two additional copies of this Information Disclosure Statement are enclosed.
- ☐ A check in the amount of \$240.00 is attached hereto in payment of the fee under 37 C.F.R. §1.17(p).
- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. It is hereby requested that the Information Disclosure Statement be considered.
- ☐ a. Each item of information contained on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).

- [] b. No item of information cited on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).
- [] Please charge Deposit Account No. 23-1665 in the amount of \$130.00 in payment of the fee under 37 C.F.R. §1.17(i)(1). Two additional copies of this Information Disclosure Statement are enclosed.
- [] A check in the amount of \$130.00 is attached hereto in payment of the fee under 37 C.F.R. §1.17(i)(1).

The undersigned represents that the closest art of which he is presently aware has been cited herein and understands that this statement shall not be construed as a representation that no better art exists or that a thorough patentability search has been made.

The undersigned further represents that the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

Respectfully submitted,

PER-ÅKE NYGREN, ET AL.


Date: 16 MAY 2003

By: Todd E. Garabedian

Todd E. Garabedian, Ph.D.
Registration No. 39,197
Attorney for Applicants

WIGGIN & DANA LLP
One Century Tower
New Haven, CT 06508-1832

Telephone : (203) 498-4400
Telecopier: (203) 782-2889

INFORMATION DISCLOSURE STATEMENT BY APPLICANT 		ATTY. DOCKET NO. 102359-100	SERIAL NO. 10/030,652			
		APPLICANT: PER-ÅKE NYGREN, MATHIAS UHLÉN and OLOF NORD				
		FILING DATE: November 9, 2001	GROUP:			
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL*	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPR.
~	5,9670,483	09/23/97	Zhang, Shuguang, et al.	A61K	703	
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION Yes No
~	WO 95/19374	07/20/95	WO	C07K	14705	Yes
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)						
~	HOOGENBOOM, H R ET AL: IMMUNOTECHNOLOGY, Vol. 4, Pages 1-20 (1998).					
~	STAHL, S and NYGREN, P-A: PATOLOGIE BIOLOGIE, Vol. 45, Pages 66-76 (1997).					
~	JANSSON, B ET AL: FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, Vol. 20, Pages 69-78 (1998).					
~	NYGREN, P-A and UHLEN, M: CURRENT OPINION IN STRUCTURAL BIOLOGY, Vol. 7, Pages 463-469 (1997).					
~	CORTESE, R ET AL: CURRENT OPINION IN BIOTECHNOLOGY, Vol. 6, Pages 73-80 (1995).					
~	CLACKSON, T and WELLS, J A: TRENDS IN BIOTECHNOLOGY, Vol. 12, Pages 173-184 (1994).					
~	SMITH, G P and PETRENKO, V A: AMERICAN CHEMICAL SOCIETY, Vol. 97, Pages 391-410 (1997).					
~	HANES, J and PLUCKTHUN, A: <i>In Vitro</i> selection and evolution of functional proteins by using ribosome display, PROCEEDINGS, NATIONAL ACADEMY OF SCIENCES OF THE USA, Vol. 94, Pages 4937-4942 (May, 1997).					
~	SCHATZ, P J: BIOTECHNOLOGY, Vol. 11, Pages 1138-1143 (October, 1993).					
~	ROBERTS, R W and SZOSTAK, J W: RNA-peptide fusions for the <i>in vitro</i> selection of peptides and proteins, PROCEEDINGS, THE NATIONAL ACADEMY OF SCIENCES OF THE USA, Vol. 94, Pages 12297-12302 (November, 1997).					
~	McBRIDE, J D ET AL: JOURNAL OF MOLECULAR BIOLOGY, Vol. 259, Pages 819-827 (1996).					
~	NORD, K ET AL: PROTEIN ENGINEERING, Vol. 8, Issue 6, Pages 601-608 (1995).					
~	LU, Z ET AL: BIOTECHNOLOGY, Vol. 13, Pages 366-372 (April, 1995).					
EXAMINER: MARK NAVARRO			DATE CONSIDERED: 1/26/05			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \15623\4\402634.1						

INFORMATION DISCLOSURE STATEMENT BY APPLICANT MAY 19 2003 PATENT & TRADEMARK OFFICE		ATTY. DOCKET NO. 102359-100		SERIAL NO. 10/030,652		
		APPLICANT: PER-ÅKE NYGREN, MATHIAS UHLÉN and OLOF NORD				
		FILING DATE: November 9, 2001		GROUP:		
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL*	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROP.
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION Yes No
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)						
~	BODER, E T and WITTRUP, K D: NATURE BIOTECHNOLOGY, Vol. 15, Pages 553-557 (June, 1997).					
~	ERNST, W ET AL: NUCLEIC ACIDS RESEARCH, Vol. 26, No. 7, Pages 1718-1728 (1998).					
~	GRABHERR, R ET AL: BIOTECHNIQUES, Vol. 22, Pages 730-735 (April, 1997).					
~	RÜTHER, U: NUCLEIC ACIDS RESEARCH, Vol. 10, No. 19, Pages 5765-5772 (1982).					
~	NYGREN, P-A ET AL: JOURNAL OF MOLECULAR RECOGNITION, Vol. 1, No. 2, Pages 69-74 (1988).					
~	CAROTHERS, A M ET AL: BIOTECHNIQUES, Vol. 7, No.5, Pages 494-499 (1989).					
EXAMINER: MARK NAVARRO		DATE CONSIDERED: 1/26/05				

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 \15623\4\402634.1